 GENEVA, Switzerland and BOSTON, MA April 30, 2021 ObsEva SA NASDAQ: OBSV SIX: OBSN a biopharmaceutical company developing and commercializing novel therapies to improve womens reproductive health, today announced the presentation of five e-Posters on linzagolix in the treatment of uterine fibroids at the American College of Obstetricians and Gynecologists ACOG Annual Clinical and Scientific Meeting ACSM, which will take place virtually from April 30 to May 2, 2021. 